Report Detail

Medical Devices & Consumables (Post-pandemic Era)-Global Clinical Oncology Next Generation Sequencing (NGS) Market Segment Research Report 2022

  • RnM4476716
  • |
  • 04 August, 2022
  • |
  • Global
  • |
  • 121 Pages
  • |
  • XYZResearch
  • |
  • Medical Devices & Consumables

Summary

The global and Chinese economies were hit hard in 2020, and the global GDP grew by 5.9% in 2021. Although the global growth prospects improved and there was a V-shaped rebound, this does not mean that the economy has really recovered to the level before the epidemic. The vast majority of countries are still in the stage of recovery after heavy damage and are far from achieving real recovery.

2022 is a year of continuous recovery. Global supply chain disturbance, geopolitical tension, energy price fluctuation, local labor shortage and rising raw material prices will affect the resilience of economic recovery. The International Monetary Fund (IMF) predicts that the world economy will grow by 4.4% in 2022, of which the U.S. economy will grow by about 4%. Driven by China and India, Asia is expected to become the fastest growing region in the world in 2022. However, China's economic growth has slowed down. The 2022 government work report shows that the expected target of economic growth is set at about 5.5%.

According to research, China has set a growth rate of about 5.5%, which not only focuses on the speed of economic growth, but also anchors the quality of economic development. Scientific and technological innovation, economic and social digitization and green development will be the long-term goals of China's economic development. It is expected that in 2022, major economies such as the United States, Europe and China will introduce more favorable policies to drive the development of switching power supply industry.

Beijing Yanjing Bizhi Information Consulting Co., Ltd. (XYZResearch)released the 《(Post-pandemic Era)-Global Clinical Oncology Next Generation Sequencing (NGS) Market Segment Research Report 2022》, which aims to sort out the development status and trends of the Clinical Oncology Next Generation Sequencing (NGS) industry at home and abroad, estimate the overall market scale of the Clinical Oncology Next Generation Sequencing (NGS) industry and the market share of major countries, Clinical Oncology Next Generation Sequencing (NGS) industry, and study and judge the downstream market demand of Clinical Oncology Next Generation Sequencing (NGS) through systematic research, Analyze the competition pattern of Clinical Oncology Next Generation Sequencing (NGS), so as to help solve the pain points of various stakeholders in Clinical Oncology Next Generation Sequencing (NGS) industry. This industry research report combines desktop research, qualitative interviews with insiders or experts and other methods to strive for the objectivity and integrity of conclusions and data.

Regional Segmentation (Value; Revenue, USD Million, 2018-2028) of Clinical Oncology Next Generation Sequencing (NGS) Market by XYZResearch Include
USA
Europe
China
Japan
India
Korea
Southeast Asia
Competitive Analysis; Who are the Major Players in Clinical Oncology Next Generation Sequencing (NGS) Market?
Illumina
Roche
Agilent Technologies
Knome
Genomatix Software
GATC Biotech
Oxford Nanopore Technologies
Macrogen
Life Technologies
DNASTAR
Exosome Diagnostics
Biomatters
CLC Bio
BGI
Qiagen
Perkin Elmer
Pacific Bioscience
Partek
GnuBIO
Foundation Medicine
Paradigm
Caris Life Sciences
Myriad Genetics
Major Type of Clinical Oncology Next Generation Sequencing (NGS) Covered in XYZResearch report:
NGS Pre-Sequencing
Sequencing
NGS Data Analysis
Primary, Secondary & Tertiary Data Analysis
Application Segments Covered in XYZResearch Market
Academic & Clinical Research
Hospitals & Clinics
Pharma & Biotech Entities

For any other requirements, please feel free to contact us and we will provide you customized report.


Table of Contents

    Global Clinical Oncology Next Generation Sequencing (NGS) Market Segment Research Report 2022

      1. Research Scope

        2. Market Overview

        • 2.1 Product Introduction, Application, Picture
        • 2.2 Global Clinical Oncology Next Generation Sequencing (NGS) Market by Value
          • 2.2.1 Global Clinical Oncology Next Generation Sequencing (NGS) Revenue by Type
          • 2.2.2 Global Clinical Oncology Next Generation Sequencing (NGS) Market by Value (%)
        • 2.3 Global Clinical Oncology Next Generation Sequencing (NGS) Market by Production
          • 2.3.1 Global Clinical Oncology Next Generation Sequencing (NGS) Production by Type
          • 2.3.2 Global Clinical Oncology Next Generation Sequencing (NGS) Market by Production (%)

        3. The Major Driver of Clinical Oncology Next Generation Sequencing (NGS) Industry

        • 3.1 Historical & Forecast Global Clinical Oncology Next Generation Sequencing (NGS) Demand
        • 3.2 Largest Application for Clinical Oncology Next Generation Sequencing (NGS) (2018-2028)
        • 3.3 The Major Downstream Company in China Market 2022

        4. Global and Regional Clinical Oncology Next Generation Sequencing (NGS) Market

        • 4.1 Regional Market Size in Terms of Production & Demand (2022)
        • 4.2 Regional Market Share in Terms of Revenue (2018-2022)
        • 4.3 Concentration Ratio (CR5& CR10) of Clinical Oncology Next Generation Sequencing (NGS) Market
        • 4.4 Mergers & Acquisitions, Expansion Plans

        5. US Clinical Oncology Next Generation Sequencing (NGS) Production, Demand (2018-2028)

        • 5.1 Current and Estimated Production Breakdown by Type
        • 5.2 Current and Estimated Demand Breakdown by Type
        • 5.3 Current and Estimated Demand Breakdown by Application
        • 5.4 Current and Estimated Revenue Breakdown by Type (2018-2028)
        • 5.5 Current and Estimated Revenue Breakdown by Application (2018-2028)

        6. Europe Clinical Oncology Next Generation Sequencing (NGS) Production, Demand (2018-2028)

        • 6.1 Current and Estimated Production Breakdown by Type
        • 6.2 Current and Estimated Demand Breakdown by Type
        • 6.3 Current and Estimated Demand Breakdown by Application
        • 6.4 Current and Estimated Revenue Breakdown by Type (2018-2028)
        • 6.5 Current and Estimated Revenue Breakdown by Application (2018-2028)

        7. China Clinical Oncology Next Generation Sequencing (NGS) Production, Demand (2018-2028)

        • 7.1 Current and Estimated Production Breakdown by Type
        • 7.2 Current and Estimated Demand Breakdown by Type
        • 7.3 Current and Estimated Demand Breakdown by Application
        • 7.4 Current and Estimated Revenue Breakdown by Type (2018-2028)
        • 7.5 Current and Estimated Revenue Breakdown by Application (2018-2028)

        8. Japan Clinical Oncology Next Generation Sequencing (NGS) Production, Demand (2018-2028)

        • 8.1 Current and Estimated Production Breakdown by Type
        • 8.2 Current and Estimated Demand Breakdown by Type
        • 8.3 Current and Estimated Demand Breakdown by Application
        • 8.4 Current and Estimated Revenue Breakdown by Type (2018-2028)
        • 8.5 Current and Estimated Revenue Breakdown by Application (2018-2028)

        9. India Clinical Oncology Next Generation Sequencing (NGS) Production, Demand (2018-2028)

        • 9.1 Current and Estimated Production Breakdown by Type
        • 9.2 Current and Estimated Demand Breakdown by Type
        • 9.3 Current and Estimated Demand Breakdown by Application
        • 9.4 Current and Estimated Revenue Breakdown by Type (2018-2028)
        • 9.5 Current and Estimated Revenue Breakdown by Application (2018-2028)

        10. Korea Clinical Oncology Next Generation Sequencing (NGS) Production, Demand (2018-2028)

        • 10.1 Current and Estimated Production Breakdown by Type
        • 10.2 Current and Estimated Demand Breakdown by Type
        • 10.3 Current and Estimated Demand Breakdown by Application
        • 10.4 Current and Estimated Revenue Breakdown by Type (2018-2028)
        • 10.5 Current and Estimated Revenue Breakdown by Application (2018-2028)

        11. Southeast Asia Clinical Oncology Next Generation Sequencing (NGS) Production, Demand (2018-2028)

        • 11.1 Current and Estimated Production Breakdown by Type
        • 11.2 Current and Estimated Demand Breakdown by Type
        • 11.3 Current and Estimated Demand Breakdown by Application
        • 11.4 Current and Estimated Revenue Breakdown by Type (2018-2028)
        • 11.5 Current and Estimated Revenue Breakdown by Application (2018-2028)

        12. Global Clinical Oncology Next Generation Sequencing (NGS) Average Price Trend

        • 12.1 Market Price for Each Type of Clinical Oncology Next Generation Sequencing (NGS) in US (2018-2022)
        • 12.2 Market Price for Each Type of Clinical Oncology Next Generation Sequencing (NGS) in Europe (2018-2022)
        • 12.3 Market Price for Each Type of Clinical Oncology Next Generation Sequencing (NGS) in China (2018-2022)
        • 12.4 Market Price for Each Type of Clinical Oncology Next Generation Sequencing (NGS) in Japan (2018-2022)
        • 12.5 Market Price for Each Type of Clinical Oncology Next Generation Sequencing (NGS) in India (2018-2022)
        • 12.6 Market Price for Each Type of Clinical Oncology Next Generation Sequencing (NGS) in Korea (2018-2022)
        • 12.7 Market Price for Each Type of Clinical Oncology Next Generation Sequencing (NGS) in Southeast Asia (2018-2022)

        13. Industrial Chain (Impact of COVID-19)

        • 13.1 Clinical Oncology Next Generation Sequencing (NGS) Industrial Chain Analysis
        • 13.2 Downstream
        • 13.3 Impact of COVID-19
        • 13.4 Post-pandemic Era
        • 13.5 Technology Trends of Clinical Oncology Next Generation Sequencing (NGS)

        14. Clinical Oncology Next Generation Sequencing (NGS) Competitive Landscape

        • 14.1 Illumina
          • 14.1.1 Illumina Company Profiles
          • 14.1.2 Illumina Product Introduction
          • 14.1.3 Illumina Clinical Oncology Next Generation Sequencing (NGS) Sales, Revenue (2018-2022)
          • 14.1.4 Strategic initiatives
        • 14.2 Roche
          • 14.2.1 Roche Company Profiles
          • 14.2.2 Roche Product Introduction
          • 14.2.3 Roche Clinical Oncology Next Generation Sequencing (NGS) Sales, Revenue (2018-2022)
          • 14.2.4 Strategic initiatives
        • 14.3 Agilent Technologies
          • 14.3.1 Agilent Technologies Company Profiles
          • 14.3.2 Agilent Technologies Product Introduction
          • 14.3.3 Agilent Technologies Clinical Oncology Next Generation Sequencing (NGS) Sales, Revenue (2018-2022)
          • 14.3.4 Strategic initiatives
        • 14.4 Knome
          • 14.4.1 Knome Company Profiles
          • 14.4.2 Knome Product Introduction
          • 14.4.3 Knome Clinical Oncology Next Generation Sequencing (NGS) Sales, Revenue (2018-2022)
          • 14.4.4 Strategic initiatives
        • 14.5 Genomatix Software
          • 14.5.1 Genomatix Software Company Profiles
          • 14.5.2 Genomatix Software Product Introduction
          • 14.5.3 Genomatix Software Clinical Oncology Next Generation Sequencing (NGS) Sales, Revenue (2018-2022)
          • 14.5.4 Strategic initiatives
        • 14.6 GATC Biotech
          • 14.6.1 GATC Biotech Company Profiles
          • 14.6.2 GATC Biotech Product Introduction
          • 14.6.3 GATC Biotech Clinical Oncology Next Generation Sequencing (NGS) Sales, Revenue (2018-2022)
          • 14.6.4 Strategic initiatives
        • 14.7 Oxford Nanopore Technologies
          • 14.7.1 Oxford Nanopore Technologies Company Profiles
          • 14.7.2 Oxford Nanopore Technologies Product Introduction
          • 14.7.3 Oxford Nanopore Technologies Clinical Oncology Next Generation Sequencing (NGS) Sales, Revenue (2018-2022)
          • 14.7.4 Strategic initiatives
        • 14.8 Macrogen
          • 14.8.1 Macrogen Company Profiles
          • 14.8.2 Macrogen Product Introduction
          • 14.8.3 Macrogen Clinical Oncology Next Generation Sequencing (NGS) Sales, Revenue (2018-2022)
          • 14.8.4 Strategic initiatives
        • 14.9 Life Technologies
          • 14.9.1 Life Technologies Company Profiles
          • 14.9.2 Life Technologies Product Introduction
          • 14.9.3 Life Technologies Clinical Oncology Next Generation Sequencing (NGS) Sales, Revenue (2018-2022)
          • 14.9.4 Strategic initiatives
        • 14.10 DNASTAR
          • 14.10.1 DNASTAR Company Profiles
          • 14.10.2 DNASTAR Product Introduction
          • 14.10.3 DNASTAR Clinical Oncology Next Generation Sequencing (NGS) Sales, Revenue (2018-2022)
          • 14.10.4 Strategic initiatives
        • 14.11 Exosome Diagnostics
        • 14.12 Biomatters
        • 14.13 CLC Bio
        • 14.14 BGI
        • 14.15 Qiagen
        • 14.16 Perkin Elmer
        • 14.17 Pacific Bioscience
        • 14.18 Partek
        • 14.19 GnuBIO
        • 14.20 Foundation Medicine
        • 14.21 Paradigm
        • 14.22 Caris Life Sciences
        • 14.23 Myriad Genetics

        15. Conclusion

          16. Methodology and Data Source

          Summary:
          Get latest Market Research Reports on Clinical Oncology Next Generation Sequencing (NGS). Industry analysis & Market Report on Clinical Oncology Next Generation Sequencing (NGS) is a syndicated market report, published as (Post-pandemic Era)-Global Clinical Oncology Next Generation Sequencing (NGS) Market Segment Research Report 2022. It is complete Research Study and Industry Analysis of Clinical Oncology Next Generation Sequencing (NGS) market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

          Last updated on

          REPORT YOU MIGHT BE INTERESTED

          Purchase this Report

          $2,850.00
          $5,700.00
          2,362.65
          4,725.30
          2,801.55
          5,603.10
          384,778.50
          769,557.00
          226,176.00
          452,352.00
          Credit card Logo

          Related Reports


          Reason to Buy

          Request for Sample of this report